true

BD MAX™ Respiratory Infections Portfolio

Detection of highly transmissible respiratory pathogens

Background Image

The BD MAX™️ Portfolio of Respiratory assays

The efficiency and versatility offered by the BD MAX™ System and the Respiratory portfolio facilitate high volume molecular testing for rapid diagnosis and treatment.

HOW MOLECULAR TESTING CAN HELP WITH RI DIAGNOSTIC CHALLENGES

 

Globally, every year there are an estimated 1 billion cases of seasonal influenza, of which 3 to 5 million are severe cases1

TB remains the world’s top infectious killer with 10 million contracting the disease each year and 1.5 million deaths2

Global pandemics occur when new strains occur of known respiratory viruses.

  • 2019 novel coronavirus (SARS-CoV-2) is a new strain that has not been previously identified in humans and is an international public health threat
  • Since it's outbreak, SARS-CoV-2 and its variants spread rapidely across the globe.

Diagnosis of acute respiratory infections can be difficult

  • Clinical symptoms: A number of other viruses and bacteria cause similar symptoms so much of influenza-like illness is determined not to be influenza3
  • Management of testing need: Acute respiratory infections spread easily from person to person through the air or by direct or indirect contact. Seasonal or pandemic infection drives high volumes of testing and need for rapid diagnosis to direct isolation and treatment
  • Test result accuracy: Traditional respiratory tests can be less reliable and false positive or false negative results can occur4

Rapid and accurate diagnosis is critical

  • Molecular viral testing with real-time PCR has high sensitivity
  • Molecular testing for TB provides timely results useful for high quality patient care, low contamination risk and ease of performance and speed5
  • Molecular testing is now available for SARS-CoV-2 to efficiently diagnose and inform patient

 

RESPIRATORY PORTFOLIO

Meet the BD MAX™ Respiratory Portfolio:


BD SARS-CoV-2 Reagents for BD MAX™ System

SARS-CoV-2 (N1)

SARS-CoV-2 (N2)

VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™

SARS-CoV-2 (N1)

SARS-CoV-2 (N2)

VIASURE SARS-CoV-2 Variant & Variant II Real Time PCR Detection Kit for BD MAX™

B.1.1.7 (Alpha) variant (69/70 deletion)

B.1.351 (Beta) variant (K417N mutation)

P.1 (Gamma) variant (K417T mutation)

B.1.617 (Delta) variant (P681R + L452R mutations)

BD SARS-CoV-2/Flu for BD MAX™ System

SARS-CoV-2 (N1 + N2)

Influenza A

Influenza B

VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for BD MAX™ System

Influenza A

Influenza B

Human Respiratory Syncytial Viruses (RSV)

BD MAX™ Cdiff

SARS-CoV-2 (N1)

SARS-CoV-2 (N2)

Influenza A
Influenza B
RSV

BD MAX™ MDR-TB

Mycobacterium tuberculosis complex (MTBC)

Rifampin resistance (RIF)
Isoniazid resistance (INH)

BD Respiratory Viral Panel for BD MAX™ System

SARS-CoV-2 (N1+N2)

Influenza A

Influenza B

RSV 

VISAURE Pneumocystis jirovecii Real Time PCR Detection Kit for BD MAX™ System

Pneumocystis jirovecii

VIASURE Bordetella Real Time PCR Detection Kit for BD MAX™ System

Bordetella pertussis

Bordetella parapertussis

Bordetella holmesii

The BD MAX™ System is a single platform
capable of running BD and 
partner developed assays,
as well as laboratory-developed tests.

Contact us to discuss how we can support your HAI screening needs
Email us

References

INH, isoniazid; MTBC, Mycobacterium tuberculosis complex; PCR, polymerase chain reaction; RIF, rifampicin; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TB, tuberculosis

BD, the BD Logo, BD MAX™ are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved.

The BD MAX™ System, BD MAX™ Enteric Bacterial & Extended Enteric Bacterial Panels, BD MAX™ Enteric Viral Panel & BD MAX™ Enteric Viral Panel-NR, BD MAX™ Enteric Parasite Panel, BD MAX™ Vaginal Panel, BD MAX™ Check-Points CPO, BD MAX™ MRSA XT & BD MAX™ StaphSR, BD MAX™ Cdiff, BD MAX™ MDR-TB, BD SARS-CoV-2 Reagents for BD MAX™ System, BD SARS-CoV-2/Flu for BD MAX™ System, VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ System, VIASURE SARS-CoV-2, Flu (A+B) & RSV Real Time PCR Detection Kit for BD MAX™ System, VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for BD MAX™ System, VIASURE Vancomycin Resistance Real Time PCR Detection Kit for BD MAX™ System are in vitro diagnostic medical devices bearing a CE mark.

The BD MAX™ CTGC2 and BD CTGCTV2 System assays are in vitro diagnostic medical devices bearing a CE mark and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797).

  1. World Health Organization. 8 Things to know about pandemic influenza. Available at: https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza. Accessed April 2020.
  2. World Health Organization. Tuberculosis. Available at: https://www.who.int/health-topics/tuberculosis#tab=tab_1. Accessed May 2020.
  3. European Centre for Disease Prevention and Control. Factsheet about seasonal influenza. Available at: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet. Accessed April 2020.
  4. Centers for Disease Control and Prevention. Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection. Available at: https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Accessed April 2020.
  5. Eddabra R and Ait Benhassou H. Pneumonia. 2018;10:4. Published 2018 May 25.
true